Cite
HARVARD Citation
Prawira, A. et al. (n.d.). 384 A Phase 1 study to evaluate the safety, PK, and antitumor activity of AK117, an anti-CD47 monoclonal antibody, in subjects with relapsed/refractory advanced or metastatic solid tumors or lymphomas. Journal for immunotherapy of cancer. p. A409. [Online].